14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study

Abstract

Feifei Lu,1,2,* Wentao Xu,2,* Xiaoye Shi,2,* Honglu Yu,2,* Xingshun Qi1,2 1College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, 110167, People’s Republic of China; 2Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110840, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xingshun Qi, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning Province, 110840, People’s Republic of China, Email [email protected]: Until now, there is little evidence regarding clinical efficacy of 14-day vonoprazan-based bismuth quadruple therapy (BQT) for Helicobacter pylori (H. pylori) eradication.Methods: Overall, 65 treatment-naïve patients with H. pylori infection who received 14-day vonoprazan-based BQT regimen (VBCA, n=17) or pantoprazole-based BQT regimen (PBCA, n=48) for H. pylori eradication were retrospectively included.Results: Neither successful H. pylori eradication (88.2% versus 91.7%, p=1.000) nor adverse event (52.9% versus 64.6%, p=0.397) was significantly different between VBCA and PBCA groups.Conclusion: Vonoprazan seems to be as effective and safe as pantoprazole during a 14-day BQT regimen in treatment-naïve patients with H. pylori infection.Keywords: Helicobacter pylori, vonoprazan, pantoprazole, bismuth quadruple therapy, efficacy

Keywords

• helicobacter pylori
• vonoprazan
• pantoprazole
• bismuth quadruple therapy
• efficacy.